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Replication and transcription activator (Rta), a key protein expressed by Epstein–Barr
virus (EBV) during the immediate-early stage of the lytic cycle, is responsible for the
activation of viral lytic genes. In this study, GST-pulldown and coimmunoprecipitation
assays showed that Rta interacts in vitro and in vivo with TRIM5α, a host factor known to
be involved in the restriction of retroviral infections. Confocal microscopy results revealed
that Rta colocalizes with TRIM5α in the nucleus during lytic progression. The interaction
involves 190 amino acids in the N-terminal of Rta and the RING domain in TRIM5α,
and it was further found that TRIM5α acts as an E3 ubiquitin ligase to promote Rta
ubiquitination. Overexpression of TRIM5α reduced the transactivating capabilities of Rta,
while reducing TRIM5α expression enhanced EBV lytic protein expression and DNA
replication. Taken together, these results point to a critical role for TRIM5α in attenuating
EBV lytic progression through the targeting of Rta for ubiquitination, and suggest that
the restrictive capabilities of TRIM5α may go beyond retroviral infections.
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INTRODUCTION
Epstein–Barr virus (EBV), a member of the human herpesvirus family, is an oncogenic virus that
infects lymphoid and epithelial cells. Although EBV normally remains latent after infecting B
lymphocyte cells, the virus must enter the lytic cycle to proliferate and produce infectious particles.
The pivotal role of the two EBV intermediate-early proteins, Replication and transcription activator
(Rta) and Zta, in activating the transcription of EBV lytic genes is well-documented (Speck et al.,
1997; Zalani et al., 1997; Liu and Speck, 2003; Amon and Farrell, 2005). In previous studies, we
showed that Rta is conjugated to SUMO-1 by Ubc9 and PIAS (protein inhibitor of activated STAT)
proteins, and this sumoylation enhances Rta transactivation activity (Chang et al., 2004). Rta is
also modified by SUMO-2 (Heilmann et al., 2010), and can be ubiquitinated via the SUMO chain
by a SUMO-targeted E3 ubiquitin ligase, RNF4, thereby inhibiting EBV lytic activation (Yang et al.,
2013).
In this study, we identified a second E3 ubiquitin ligase that promotes Rta ubiquitination to
influence EBV lytic progression, TRIM5α. TRIM5α is a member of the tripartite motif (TRIM)
protein superfamily, and acts as a host restriction factor that limits retroviral infection (Stremlau
et al., 2004; Pertel et al., 2011). Earlier studies have shown that TRIM5α from rhesus macaques
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(rhTRIM5α) restricts early events in human immunodeficiency
virus (HIV)-1 infection, while human TRIM5α restricts infection
by N-tropic murine leukemia virus (N-MLV) (Yap et al.,
2004). As an intrinsic immunity protein, TRIM5α catalyzes
the synthesis of unanchored K63-linked polyubiquitin chains,
and then activates NF-κB or AP-1 dependent transcription
(Pertel et al., 2011). TRIM5α contains B boxes, a coiled-coil
domain, and a RING domain, and can function as an E3
ubiquitin ligase (Reymond et al., 2001). In addition, TRIM5α
contains a SPRY/B30.2 domain with two SUMO-interaction
motifs (SIMs), which are required for N-MLV restriction
(Arriagada et al., 2011). This SPRY/B30.2 domain can also
directly bind with the HIV capsid, and is believed to be
critical for HIV restriction (Sawyer et al., 2005; Stremlau et al.,
2005; Luban, 2007; Ganser-Pornillos et al., 2011). Moreover,
TRIM5α-mediated ubiquitin conjugation is required for HIV-
1 capsid destabilization and inhibition of reverse transcription
(Campbell et al., 2016). Interestingly, SIM mutations in TRIM5α
not only lead to loss of restriction capability against N-MLV
(Arriagada et al., 2011), but the mutations also prevent TRIM5α
from shuttling into the cell nucleus, thus rendering it unable to
restrict incoming HIV retrovirion cores (Brandariz-Nunez et al.,
2013).
Although TRIM5α primarily acts to limit the propagation
of retroviruses (Hatziioannou et al., 2004; Keckesova et al.,
2004; Perron et al., 2004; Stremlau et al., 2004; Yap et al.,
2004), it has been reported that rhTRIM5α can hamper the
replication of herpes simplex virus (HSV) (Reszka et al., 2010),
a double-stranded DNA virus. In this study, we identified
an interaction between TRIM5α and the EBV viral protein,
Rta, using GST-pulldown and coimmunoprecipitation assays.
TRIM5α and Rta colocalized in the nucleus, and we further
found that TRIM5α can act as an E3 ubiquitin ligase that
promotes Rta ubiquitination. This subsequently leads to the
downregulation of Rta transactivation capabilities, indicating
that TRIM5α may play a critical role in attenuating EBV
lytic progression. These results suggest that the restrictive
abilities of TRIM5α are not limited to retroviruses, and
may have interesting implications for antiviral research and
development.
MATERIALS AND METHODS
Cell Lines and EBV Lytic Induction
P3HR1, a Burkitt’s lymphoma cell line latently infected by EBV
(Ben-Bassat et al., 1976), was cultured in RPMI1640 medium
containing 10% fetal calf serum. 293T cells were cultured in
Dulbecco’s modified Eagle’s medium (DMEM) containing 10%
fetal calf serum. P3HR1 cells were treated with 30 ng/mL 12-
O-tetradecanoylphorbol-13-acetate (TPA) and 3 mM sodium
butyrate to activate the EBV lytic cycle (Luka et al., 1979; Davies
et al., 1991; Chang and Liu, 2000).
Plasmids
Plasmids pGEX-TRIM5α and pEGFP-TRIM5α were constructed
by inserting a DNA fragment, which was amplified by
PCR using pLPCX-TRIM5α as a template (NIH AIDS
reagent program, USA) and the primers TRIM5α-F (5′-
CCGGAATTCATGGCTTCTGGAATCCTGGT) and TRIM5α-R
(5′-ACGCGTCGACTCAAGAGCTTGGTGAGCACA), into the
EcoRI and SalI sites in pGEX-4T1 (Amersham) and pEGFP-C2
(Clontech), respectively. DNA fragments, which encode the
regions in TRIM5α from amino acids 1 to 261, 81 to 493, and
261 to 493 were amplified by PCR. These DNA fragments
were then inserted into the EcoRI and SalI sites in pEGFP-
C2 to generate pEGFP-TRIM5α-dC, pEGFP-TRIM5α-dN,
and pEGFP-TRIM5α-dNM, respectively. The DNA fragment
from amino acids 1 to 261 was also inserted into pTag2B
to create pFlag-TRIM5α-dC. Plasmids that express deletion
mutants of GFP-Rta, including GFP-N190, GFP-N191/415,
and GFP-Rev have been described previously (Hsu et al.,
2005; Chang et al., 2010; Yang and Chang, 2013). Plasmids
pFlag-Ub, pFlag-Rta, and pET-Rta, which express Flag-tagged
ubiquitin, Flag-tagged Rta and His-tagged Rta, were described
earlier (Yang et al., 2013). For transient transfection assays,
the reporter plasmid, pBMRF1, was constructed by inserting
a PCR-amplified DNA fragment containing the −172 to +20
region in BMRF1 into pGL2-Basic (Chang et al., 2010). Plasmid
pBMLF1-RRE containing the RRE sequence from the BMLF1
promoter and a TATA sequence was synthesized and inserted
into pGL2-Basic (Chang et al., 2004). Similarly, the RRE
sequence from the BMRF1 promoter and a TATA sequence
was synthesized and inserted into pGL2-Basic to generate
pBMRF1-RRE.
MALDI-TOF Mass Spectrometry
P3HR1 cells were treated with TPA and sodium butyrate for
24 h to activate the EBV lytic cycle and Rta expression. Cells
were harvested by low speed centrifugation and lysed using
mRIPA buffer (50 mM Tris-HCl (pH 7.8), 150 mM NaCl,
5 mM EDTA, 0.5% Triton X-100, 0.5% Nonidet P-40), and
proteins in the lysate were immunoprecipitated using anti-
Rta antibody and protein A/G-agarose beads (Millipore). The
beads were washed with mRIPA buffer for three times, and
proteins on the beads were then extracted with electrophoresis
sample buffer (10% glycerol, 60 mM Tris-HCl pH 6.8, 2% SDS,
2.5% β-mercaptoethanol, 2 mM EDTA) and subjected to 2-
D polyacrylamide gel electrophoresis. Proteins in the gel were
stained with Coomassie blue, and prospective protein spots in the
gel were then excised. The proteins in the spots were digested with
trypsin according to an in-gel digestion protocol (Shevchenko
et al., 1996), and the resulting peptides were analyzed using
a Bruker Biflex III MALDI-TOF mass spectrometer (Bruker
Daltonics) (Wu et al., 2007). The m/z ratios of the digested
peptides and their fragmented ions were used to search the
annotated human genome in the Mass Spectrometry protein
sequence Database (MSDB), using Mascot search software
v1.8 (Matrix Science Inc). The search criteria used were as
follows: maximum of one missed trypsin cleavage; variable
modification, including carbamidomethylation; and 1 Da peptide
mass tolerance. Only proteins identified as significant hits
(p < 0.05) by Mascot peptide mass fingerprint search were
selected.
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Protein Expression and GST Pulldown
Assay
Escherichia coli BL21(DE3)(pGEX-TRIM5α) and E. coli
BL21(DE3)(pGST) were cultured to the mid-log phase and then
treated with 0.1 mM isopropyl β-D-1-thiogalactopyranoside
(IPTG) to, respectively, induce the expression of GST-TRIM5α
and GST according to a method described earlier (Chang
et al., 2004). GST and GST-TRIM5α were purified from
bacterial lysates using glutathione-Sepharose 4B beads (GE
healthcare).
Transient Transfection and Luciferase
Assay
293T cells were transfected with plasmids using Turbofect
(Thermo Fisher Scientific), according to the method
recommended by the manufacturer. At 24–48 h after
transfection, cells were harvested and lysed using mRIPA
lysis buffer [50 mM Tris-HCl (pH 7.8), 150 mM NaCl, 5 mM
EDTA, 0.5% Triton X-100, 0.5% Nonidet P-40]. Luciferase assays
were performed according to a method described earlier (Chang
et al., 1998).
Coimmunoprecipitation of Rta and
TRIM5α
293T cells were transfected with pCMV-Rta and pHA-
TRIM5α, and at 24 h after transfection, cells were collected
and lysed in mRIPA buffer. Proteins in the lysate were
immunoprecipitated with anti-Rta and anti-HA antibodies.
Protein A/G-agarose beads were then added to the lysate, and
proteins bound to the beads were subsequently analyzed
by immunoblotting. To detect ubiquitinated proteins,
293T cells were cotransfected with pCMV-R, pTag-2B, and
pLPCX-TRIM5α. At 24 h after transfection, cells were
treated with 5 µM MG132 for additional 12 h. Cells were
harvested according to a method described earlier (Chang
et al., 2004; Yang et al., 2013) to detect ubiquitin-conjugated
proteins.
Immunoblot Analysis
Proteins were separated in SDS-polyacrylamide gels and then
electrotransferred to Hybond C membranes (GE) at 90 V for
1 h, according to a method described elsewhere (Chang et al.,
2004). The membrane was then probed with the appropriate
antibodies, including anti-Rta (Argene), anti-TRIM5α (Santa
Cruz), anti-HA (Roche), anti-GFP (Santa Cruz), anti-GST (Santa
Cruz), anti-VCA (Argene), anti-BFRF3 (Wang et al., 2015), and
anti-α-tubulin (Sigma) antibodies.
Immunofluorescence Analysis
P3HR1 cells were treated with sodium butyrate and TPA for 24 h,
harvested by centrifugation, plated on poly-L-lysine (Sigma)-
coated coverslips, and fixed with 4% paraformaldehyde in PBS
for 30 min. Immunostaining was conducted using anti-Rta
monoclonal antibodies (Argene) and anti-TRIM5α polyclonal
antibodies (Santa Cruz). Cells were then treated with Alexa
Fluor R© 594 goat anti-mouse and Alexa Fluor R© 488 goat anti-
rabbit antibodies (Invitrogen). Nuclei were visualized by staining
with 5 mg/mL 4′-6-diamidino-2-phenylindole (DAPI). Cells were
observed under a confocal laser scanning microscope (Leica TCS
SP8).
Knockdown of TRIM5α Expression
TRIM5α shRNA and plasmids, including pMD2.G,
pCMVDR8.91, and pLKO-shRNA, were purchased from
the National RNAi Core Facility, Genomic Research Center,
Academia Sinica, Taipei, Taiwan. 293T cells (2 × 105) were
cotransfected with plasmids expressing TRIM5α shRNA (target
sequence: 5′-CCAGACATTTGTGAATTTCAA-3′; 2.25 µg),
helper plasmids pMD2.G (0.25 µg) and pCMVDR8.91 (2.25 µg),
using Turbofect in vitro transfection reagent (Thermo Fisher
Scientific). Culture media was changed on the following
day, and after an additional 24 h, viral supernatants were
collected and filtered (0.22 µM), then stored at −80◦C. Plasmid
pLKO-shRNA was used as a negative control. For lentivirus
infection, P3HR1 cells (3 × 105/mL) were transduced with the
generated lentiviruses, together with 5 µg/mL of polybrene.
Infected P3HR1 cells were selected using 2 µg/mL puromycin
in culture medium to produce stable cell lines according to the
protocol1.
Determining Copy Numbers of EBV DNA
P3HR1 cells were treated with TPA and sodium butyrate to
induce the lytic cycle. After 5 days of culturing, virus particles
released into the medium were collected by ultracentrifugation
at 25,000 × g for 2.5 h. EBV copy numbers were determined
according to a method described previously (Ryan et al., 2004;
Chiu et al., 2007). A standard curve was established using
maxi-EBV DNA purified from E. coli after qPCR analysis. The
amounts of EBV DNA purified from the virus in the culture
medium were similarly analyzed and compared with the standard
curve.
RESULTS
Identification of Cellular Proteins
Interacting with Rta
We treated P3HR1 cells with TPA and sodium butyrate
for 24 h to activate the EBV lytic cycle and allowed the
expression of Rta. Proteins interacting with Rta were then
coimmunoprecipitated from cell lysates, using anti-Rta
antibodies. A similar immunoprecipitation experiment was
conducted using anti-IgG antibody as a control. Afterward, 2-D
polyacrylamide gel electrophoresis of the immunoprecipitated
proteins from each experiment (Figure 1A) was conducted,
and the gels were then stained with Coomassie blue and
compared. The comparison results revealed 14 protein spots
that appeared in the gel containing anti-Rta immunoprecipitated
proteins, but not in the control gel (Figure 1A). After
digesting the proteins in these spots with trypsin, the
1http://rnai.genmed.sinica.edu.tw/webContent/web/protocols
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FIGURE 1 | MALDI-TOF mass spectrometry analysis of proteins that interact with Rta. (A) P3HR1 cells were treated with TPA and sodium butyrate for 24 h
to induce the EBV lytic cycle and Rta expression. Cells were then lysed, and proteins in the lysate were immunoprecipitated (IP) with anti-Rta or anti-IgG antibodies.
Immunoprecipitated proteins were denatured and analyzed by 2-D polyacrylamide gel electrophoresis. (B) Proteins in prospective spots were digested with trypsin
and analyzed by MALDI-TOF mass spectrometry. Proteins with peptide fingerprints matching those in the MSDB database are listed in the table at right. (C) Peptide
sequences in TRIM5α matching those in the D21 proteins are underlined.
resulting peptides were analyzed by MALDI-TOF mass
spectrometry. The results revealed that five protein spots had
peptide fingerprints matching those in the MSDB database
(Figure 1B). Among these, Spot D21 had a protein with a
fingerprint matching that of TRIM5α (Figure 1C), a known
E3 ubiquitin ligase that promotes protein ubiquitination.
Since Rta is known to be modified by ubiquitin (Yang
et al., 2013), this study further sought to investigate whether
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TRIM5α influences the ubiquitination status and functions of
Rta.
Rta Interacts with TRIM5α In vitro and In
vivo
To verify the interaction between Rta and TRIM5α, we expressed
GST-TRIM5α and GST in E. coli, and bound these proteins
to glutathione-Sepharose beads. GST-TRIM5α-glutathione-
Sepharose beads were then added to E. coli BL21(DE3)(pET-Rta)
lysates, and proteins pulled down by the beads were detected
by immunoblotting with anti-Rta antibody. The results
revealed that GST-TRIM5α, but not GST-glutathione-
Sepharose beads, pulled down Rta (Figure 2A, lanes 4 and
5), providing in vitro evidence of a direct interaction between
TRIM5α and Rta. A coimmunoprecipitation experiment using
lysates from 293T cells that had been cotransfected with
pCMV-Rta and pLPCX-HA-TRIM5α similarly showed that
anti-TRIM5α antibody immunoprecipitated HA-TRIM5α
and coimmunoprecipitated Rta (Figure 2B, lanes 4 and
8), while anti-Rta antibody immunoprecipitated Rta and
coimmunoprecipitated HA-TRIM5α (Figure 2B, lanes 3 and 7).
Colocalization of TRIM5α with Rta in the
Nucleus
The localization of Rta and TRIM5α in P3HR1 cells treated
with TPA and sodium butyrate for 24 h was examined by
indirect immunofluorescence. Under a confocal laser scanning
microscope, we found that both Rta and TRIM5α formed
speckles, many of which colocalized in the cell nucleus
(Figures 3f–j). However, Rta was not observed if the cells
were not treated with TPA and sodium butyrate (Figures 3a–
e). P3HR1 cells treated with or without TPA and sodium
butyrate were also stained with secondary antibodies as a
control to demonstrate the specificity of anti-TRIM5α antibody
(Figures 3k–t).
Analysis of Interacting Domains in Rta
and TRIM5α
We cotransfected 293T cells with pFlag-TRIM5α and plasmids
expressing different segments of Rta that were fused to GFP
(Figure 4A). Control cells were cotransfected with plasmids
expressing GFP and Flag-TRIM5α. Immunoblotting with
anti-GFP antibody revealed that GFP and the GFP-Rta fusion
proteins were expressed at similar levels after transfection
(Figure 4B, lanes 1–5). Following immunoprecipitation with
anti-Flag antibody, precipitated proteins were analyzed by
immunoblotting with anti-GFP antibody. Results showed that
GFP-N190 (Figure 4B, lane 8), which contains 190 amino
acids from the N-terminal of Rta, was coimmunoprecipitated
with Flag-TRIM5α, indicating that this is the region in
Rta that interacts with TRIM5α. In addition, we also
observed a weak binding effect between TRIM5α and GFP-
N191-415 (Figure 4B, lane 9). However, GFP-Rev was not
coimmunoprecipitated by Flag-TRIM5α (Figure 4B, lane
10). A control experiment showed that Flag-TRIM5α was
not coimmunoprecipitated with GFP (Figure 4B, lane 6).
These results were reproduced from at least three independent
experiments. To identify the region in TRIM5α that interacts
with Rta, we generated plasmids expressing GFP fused to
different segments of TRIM5α (Figure 4C). Following
cotransfection of these plasmids with pFlag-Rta to 293T
cells, cells were subsequently lysed, and the lysates subjected
to immunoprecipitation using anti-Flag antibody (Figure 4D,
lanes 1–5). Immunoblot analysis with anti-GFP antibody
revealed that only GFP-TRIM5α and GFP-TRIM5α-dC were
coimmunoprecipitated with Flag-Rta (Figure 4D, lanes 7
FIGURE 2 | Interaction between Rta and TRIM5α. (A) In a GST-pulldown assay, His-Rta (lanes 3–5) was mixed with GST- (lane 4) and GST-TRIM5α- (lane 5)
glutathione-Sepharose beads. Proteins pulled down by the beads were analyzed by immunoblotting (IB) with anti-Rta antibody. Proteins on the
glutathione-Sepharose beads (lanes 1 and 2) and Rta in 1% of the lysate (lane 5) were also detected by immunoblotting. (B) Coimmunoprecipitation assay results.
Anti-Rta and anti-TRIM5α antibodies were added to the lysate from 293T cells that had been transfected with pLPCX-HA-TRIM5α and pCMV-Rta. Lanes 1 and 5
were loaded with 3% of the cell lysate. Proteins immunoprecipitated (IP) with anti-Rta and anti-TRIM5α antibodies or anti-IgG antibody were detected by
immunoblotting (IB), using anti-HA (lanes 1–4) and anti-Rta antibodies (lanes 5–8).
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FIGURE 3 | Subcellular localization of Rta and TRIM5α. P3HR1 cells were treated with sodium butyrate and TPA (SB/TPA) or DMSO (NC) for 24 h. Cells were
incubated with monoclonal anti-Rta antibody (c,h) and polyclonal anti-TRIM5α antibody (b,g). Cells were also stained with secondary antibodies (k–t) as a control.
Nuclei were visualized by DAPI staining (a,f). Cells were observed under a confocal laser-scanning microscope, and (d,e,i,j,n,o,s,t) are merged images. Scale bar
indicates 10 µm.
and 10). In addition, 293T cells were cotransfected with
plasmids encoding GFP-N190 and Flag-TRIM5α-dC, and
immunoblot analysis revealed that GFP-N190 in cell lysates
(Figure 4E, lane 3) was immunoprecipitated by anti-Flag
antibody (Figure 4E, lane 3). However, control cells that
were cotransfected with plasmids expressing GFP and Flag-
TRIM5α-dC revealed that GFP was not coimmunoprecipitated
with Flag-TRIM5α-dC (Figure 4E, lane 2). These results indicate
that the N-terminal of Rta interacts with the N-terminal RING
domain in TRIM5α.
TRIM5α Promotes Rta Ubiquitination
TRIM5α has previously been shown to be an E3 ubiquitin ligase
(Yamauchi et al., 2008), and the observation of Rta-TRIM5α
interaction prompted us to investigate whether TRIM5α can
influence Rta ubiquitination. We proceeded to transfect 293T
cells with pCMV-Rta alone, or with pCMV-Rta and pFlag-Ub.
At 24 h after transfection, cells were treated with MG132, a
proteasome inhibitor, to prevent the degradation of Rta. When
proteins from the lysates of cells transfected with pCMV-Rta
alone were immunoprecipitated using anti-Flag antibody and
assessed by immunoblotting with anti-Rta, a single non-specific
band of about 95 kDa was detected (Figure 5A, lane 1), which
was also observed in previous studies (Chang et al., 2004; Yang
et al., 2013). In 293T cells cotransfected with pCMV-Rta and
pFlag-Ub, low amounts of ubiquitinated Rta were detected after
the proteins in the lysates were immunoprecipitated with anti-
Flag antibody and assessed by immunoblotting with anti-Rta
antibody (Figure 5A, lane 2). When cells were cotransfected
with pCMV-Rta, pFlag-Ub, and 0.3 or 0.6 µg of pLCPX-
TRIM5α, ubiquitinated Rta became more prominent (Figure 5A,
lanes 3 and 4), demonstrating that TRIM5α promotes Rta
ubiquitination. Subsequently, 293T cells were transfected with
TRIM5α shRNA to determine whether this would reduce Rta
ubiquitination. In a control experiment, immunoblotting did not
detect ubiquitinated Rta in cells that were transfected with pHA-
Ub (Figure 5B, lane 1). Ubiquitinated Rta was also detected
in cells that were cotransfected with pFlag-Rta and pHA-Ub
(Figure 5B, lane 2). However, introducing TRIM5α shRNA
reduced the amounts of ubiquitinated Rta (Figure 5B, lanes
3 and 4).
Influence of TRIM5α on Rta
Transactivation Activity
It is known that Rta acts as a key immediate-early protein
that transactivates viral lytic genes to move EBV into the
lytic cycle. Therefore, we sought to evaluate the impact of
enhanced TRIM5α expression and Rta ubiquitination on the
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FIGURE 4 | Mapping the interaction domains in Rta and TRIM5α. (A) Plasmids that expressed GFP fused to different segments of Rta were used to delineate
the region in Rta that interacts with TRIM5α. (B) 293T cells were cotransfected with pFlag-TRIM5α and plasmids expressing GFP or GFP-Rta fusion proteins
(pEGFP-Rta, pEGFP-N190, pEGFP-N191-415, pEGFP-Rev, or pEGFP-C1). Input lanes were loaded with 5% of the lysate (lanes 1–5). Proteins in the lysates were
coimmunoprecipitated (IP) with anti-Flag antibody and analyzed by immunoblotting (IB) using anti-GFP antibody (lanes 6–10). (C) Plasmids expressing various
GFP-TRIM5α fusion proteins (GFP-TRIM5α, GFP-TRIM5α-dN, GFP-TRIM5α-dNM, GFP-TRIM5α-dC) were generated. (D) 293T cells were cotransfected with
plasmids encoding GFP or GFP-TRIM5α fusion proteins (GFP-TRIM5α, GFP-TRIM5α-dN, GFP-TRIM5α-dNM, GFP-TRIM5α-dC). Input lanes were loaded with 5% of
the lysate, and GFP-fusion protein expression levels were detected using anti-GFP antibody (lanes 1–5). Proteins in the lysates were coimmunoprecipitated with
anti-Flag antibody and analyzed by immunoblotting using anti-GFP antibody (lanes 6–10). (E) 293T cells were cotransfected with pFlag-TRIM5α-dC and plasmids
expressing either GFP-N190 or GFP. Input lanes were loaded with 5% of the lysate. Proteins in the lysates were coimmunoprecipitated with anti-Flag antibody and
analyzed by immunoblotting using anti-GFP antibody.
FIGURE 5 | Enhancement of Rta ubiquitination by TRIM5α. (A) 293T cells were cotransfected with plasmids expressing Rta, Flag-ubiquitin, and TRIM5α.
Proteins in the lysates were immunoprecipitated (IP) using anti-Flag antibody and assessed by immunoblotting (IB) with anti-Rta antibody. (B) 293T cells were
cotransfected with plasmids pFlag-Rta, pHA-Ub, and pLKO-shTRIM5α, which encoded Flag-Rta, HA-ubiquitin and shTRIM5α, respectively. Proteins in the lysates
were immunoprecipitated (IP) using anti-Flag antibody and analyzed by immunoblotting (IB) with anti-HA antibody. At 24 h after transfection, cells were treated with
5 µM MG132 for additional 12 h to inhibit proteasome degradation. The asterisk indicates a non-specific band, also detected in previous studies (Chang et al., 2004;
Yang et al., 2013). Ub-Rta, ubiquitinated Rta.
transactivation capabilities of Rta. In a transient transfection
assay, we examined how TRIM5α expression can influence
Rta transactivation of the EBV BMRF1 promoter, using a
luciferase reporter plasmid, pBMRF1 (Chang et al., 2004). After
cotransfecting 293T cells with pCMV-Rta and pBMRF1, Rta
transactivation of BMRF1 was measured by luciferase activity,
and the values were taken as 100% (Figure 6A). We further
included 0.1–0.4 µg of pLPCX-TRIM5α in cotransfections, and
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FIGURE 6 | Reduction of Rta transactivation activity by TRIM5α. 293T cells were cotransfected with pCMV-R, pLPCX-TRIM5α, and (A) pBMRF1, (B)
pBMRF1-RRE, or (C) pBMLF1-RRE. Luciferase activities were assessed 24 h after transfection. Each transfection experiment was performed three times, and each
sample in the experiment was prepared in duplicate. Rta, TRIM5α, and α-tubulin expressed by the cells were examined by immunoblotting (IB). The data obtained
from the reporter assay were subjected to one-way analysis of variance (ANOVA) using SPSS software 12.0. P-values of <0.05 were considered statistically
significant. RLU, relative light units.
found that enhanced expression of TRIM5α gradually reduced
BMRF1 promoter activation in a dose-dependent manner to just
37–80% (Figure 6A). A similar experiment also showed that
cotransfection of pLPCX-TRIM5α similarly disrupted the ability
of Rta to transactivate the BMRF1-RRE (Figure 6B) and BMLF1-
RRE (Figure 6C) promoters, which contain Rta-responsive
elements (RREs). These results show that overexpression of
TRIM5α decreases Rta transactivation capability.
Influence of TRIM5α on the Expression of
EBV Lytic Proteins and Virion Production
P3HR1 cells were infected with lentivirus expressing TRIM5α
shRNA or control shRNA, and cells were then treated with
TPA and sodium butyrate to activate the EBV lytic cycle. We
found that, compared with cells infected with control shRNA,
infection by lentivirus expressing TRIM5α shRNA caused cells
to express less TRIM5α, but more Rta and EA-D (Figure 7A).
The expression of TRIM5α shRNA also led to increases in
the expression of two EBV capsid proteins, VCA and BFRF3
(Figure 7B). Quantitative PCR results showed that after lytic
activation of P3HR1 cells infected with lentivirus expressing
control shRNA, viral yield was estimated at 3× 105 EBV particles.
However, for cells infected with lentivirus expressing TRIM5α
shRNA, viral yields increased 400% to 1.2 × 106 viral particles
(Figure 7C). These results showed that TRIM5α expression
serves to attenuate EBV lytic development.
DISCUSSION
Rta is a key immediate-early viral protein that is responsible for
activating the transcription of EBV lytic genes, thereby triggering
the viral lytic cascade (Liu and Speck, 2003; Amon and Farrell,
2005; Hsu et al., 2005). In this study, we utilized MALDI-TOF
mass spectrometry to identify host proteins that can interact with
Rta and affect Rta activation of the EBV lytic cycle. From the mass
spectrometry results, we identified TRIM5α as an Rta-interacting
protein (Figure 1). Considering that TRIM5α is a known E3
ubiquitin ligase (Yamauchi et al., 2008), while Rta ubiquitination
has also been reported to affect its transactivation capabilities
(Yang et al., 2013), we therefore sought to confirm whether
TRIM5α influences Rta ubiquitination, and if so, whether Rta
transactivation ability is affected as a result. Our results also
suggest that TRIM5α may be abundantly present in P3HR1
cells, as levels of TRIM5α were detectable by Coomassie blue
staining of a 2-D polyacrylamide gel. Our previous studies
identified cellular Rta-interacting proteins, such as MCAF1
and ATF2 (Chang et al., 2005; Lin et al., 2014), which were
not detected by MALDI-TOF mass spectrometry analysis. It
is likely that the amounts of these proteins binding to Rta
are less than that of TRIM5α, causing the proteins to escape
detection. In order to validate the interaction between Rta and
TRIM5α, we conducted a GST-pulldown assay, and showed that
GST-TRIM5α-glutathione-Sepharose beads pulled down His-Rta
(Figure 2A, lane 5) via the N-terminal region in Rta and the
N-terminal RING domain in TRIM5α (Figure 4). Conversely,
anti-Rta antibody was also shown to coimmunoprecipitate HA-
TRIM5α (Figure 2B, lanes 3 and 8). Confocal microscopy results
revealed that Rta colocalizes with TRIM5α in the nuclei of P3HR1
cells after EBV lytic induction (Figure 3). Taken together, these
results corroborate the mass spectrometry findings, and provide
supporting evidence for Rta-TRIM5α interaction. Interestingly,
previous studies have shown that TRIM5α primarily resides
in the cytoplasm, so as to defend against incoming retroviral
virions (Stremlau et al., 2004). We also examined the subcellular
localization of GFP-TRIM5α and TRIM5α in 293T cells, and
found that TRIM5α formed dots in the cytoplasm (data not
shown). However, our findings suggest that the majority of
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FIGURE 7 | Influence of TRIM5α on EBV lytic progression. (A) P3HR1 cells were infected by lentivirus expressing TRIM5α shRNA (shTRIM5α) or control shRNA
(Ct-shRNA). Thereafter, cells were treated with sodium butyrate and TPA (SB/TPA) for 48 h, and proteins in the lysates were examined by immunoblotting with
anti-Rta, anti-EA-D, anti-TRIM5α, and anti-α-tubulin antibodies. (B) Cells were lysed at 120 h after TPA and sodium butyrate treatment, and the expression of VCA,
BFRF3, and α-tubulin was examined by immunoblotting. (C) An EBV lytic DNA replication assay was conducted by qPCR to determine the copy numbers of EBV
DNA. The amount of EBV DNA was determined by standard curve, which was in turn established using maxi-EBV DNA purified from E. coli after qPCR analysis. The
data were subjected to one-way analysis of variance (ANOVA) using SPSS software 12.0. P-values of <0.05 were considered statistically significant.
TRIM5α is present in the nuclei of P3HR1 cells, rather than the
cytoplasm (Figure 3). Whether this is an anomaly that exists only
in P3HR1 or lymphocyte cells, or a response to activation of the
viral lytic cycle by previously latent EBV in the cell nuclei remains
to be determined. It has been reported that TRIM5α can shuttle
between the cytoplasm and nucleus in a manner that is dependent
on amino acids 60–93 in the N-terminal of TRIM5α, although
there is no significant influence to the antiviral activity (Diaz-
Griffero et al., 2011). Still, the factors driving TRIM5α shuttling
have not been identified as yet, and it is possible that TRIM5α
may relocate in response to different viral insults, via mechanisms
that remain to be elucidated.
TRIM5α is known to act as an E3 ubiquitin ligase, and
here we found that TRIM5α can promote Rta ubiquitination
(Figure 5A). Introducing TRIM5α shRNA inhibits the levels of
ubiquitinated Rta in 293T cells (Figure 5B). However, we were
unable to detect the difference in the amounts of ubiquitinated
Rta before and after the knockdown of TRIM5α in P3HR1 cells.
EBV is known to express at least three deubiquitinases, including
BSLF1, BPLF1, and BXLF1 (Schlieker et al., 2005; Sompallae
et al., 2008). This may stabilize Rta, making the detection of
its ubiquitination in P3HR1 cells more difficult. We also found
that USP11, a deubiquitinase that acts against RNF4 activity
(Hendriks et al., 2015), removes the ubiquitin chains on Rta
efficiently (Chen et. al., unpublished results), suggesting that the
ubiquitination of Rta is tightly regulated under physiological
conditions. Additionally, overexpression of TRIM5α appears to
hamper Rta transactivation of the EBV lytic cycle, as intracellular
amounts of Rta, EA-D, BFRF3, and VCA viral lytic proteins in
P3HR1 cells treated with sodium butyrate and TPA decreased
with TRIM5α overexpression; moreover, expression of TRIM5α
reduced the number of EBV virions produced by P3HR1 cells
(Figure 7). In a transient transfection study, we showed that
the ability of Rta to transactivate three EBV lytic promoters is
negatively affected in a dose-dependent manner by enhanced
expression of TRIM5α (Figure 6). Furthermore, the expression of
TRIM5α shRNA significantly increased the number of EBV viral
particles produced by P3HR1 cells treated with sodium butyrate
and TPA (Figure 7). These results show that TRIM5α expression
attenuates Rta ability to activate the transcription of EBV lytic
genes and promote EBV lytic development, and suggests that the
antiviral properties of TRIM5α may extend beyond retroviruses.
So far, only a few proteins, including NK-κB and hTERT, are
known to decrease the lytic potential of EBV (Cahir-McFarland
et al., 2000; Terrin et al., 2007). Among these two proteins, NK-
κB is known to inhibit EBV lytic transcription and replication
(Brown et al., 2003), while hTERT disrupts the EBV lytic cycle
via a mechanism that is as yet unclear (Terrin et al., 2007). Our
previous research indicated that RNF4 can target SUMO-2-Rta
to enhance the ubiquitination of Rta, thereby inhibiting EBV
lytic progression (Yang et al., 2013). Here, we report another
cellular protein, TRIM5α, which also can play a negative role
in hampering EBV lytic development. It is known that Rta is
constitutively expressed, particularly in epithelial cells (Zalani
et al., 1992). The presence of TRIM5α may reduce Rta expression
levels at this stage and allow the virus to be maintained in
latency. Further research into the role of TRIM5α and its ability
to influence EBV and other viral physiology may be warranted.
In summary, we demonstrate that an E3 ubiquitin
ligase, TRIM5α, can interact in the cell nucleus with the
EBV immediate-early protein, Rta. TRIM5α promotes Rta
ubiquitination, and this subsequently disrupts Rta ability to
transactivate EBV lytic genes. Overexpression of TRIM5α was
found to reduce viral promoter activation and viral lytic gene
expression in a dose-dependent manner. Moreover, TRIM5α
reduced EBV virion production in P3HR1 cells treated with
sodium butyrate and TPA to induce EBV lytic activation, while
the application of TRIM5α shRNA significantly increased the
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production of EBV viral particles. Taken together, these results
indicate that TRIM5α can hamper Rta transactivation via the
promotion of Rta ubiquitination, and suggest that the antiviral
properties of TRIM5α may not be limited to retroviruses.
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